Update on hepatic intra-arterial chemotherapy
1Division of Hematology and Oncology, University of California, San Francisco, USA.
Oncology (Williston Park, N.Y.)
|July 1, 1997
Summary
Hepatic intra-arterial (HIA) chemotherapy for liver metastases shows mixed survival results but improved response rates and quality of life. Further research is needed to optimize its use and minimize toxicity.
Area of Science:
- Oncology
- Pharmacology
- Surgical Oncology
Background:
- Hepatic intra-arterial (HIA) chemotherapy aims to increase drug concentration at tumor sites.
- This approach has been extensively studied in patients with liver-only colorectal metastases.
Purpose of the Study:
- To evaluate the efficacy and safety of HIA chemotherapy compared to systemic chemotherapy and supportive care.
- To explore the potential of HIA chemotherapy in adjuvant settings and other diseases.
Main Methods:
- Review of four large randomized studies and two meta-analyses on HIA chemotherapy for liver metastases.
- Analysis of two randomized studies comparing HIA chemotherapy with supportive care.
- Consideration of improved surgical techniques and newer chemotherapy combinations.
Main Results:
- Four randomized studies did not show a survival advantage over systemic chemotherapy.
- Meta-analyses confirmed improved response rates and a trend toward improved survival.
- Two studies demonstrated improved survival and quality of life compared to supportive care.
- HIA chemotherapy has been associated with significant hepatobiliary toxicity and surgical complications.
Conclusions:
- HIA chemotherapy offers potential benefits in response rates and quality of life for liver metastases.
- Toxicity and surgical complications remain significant challenges.
- Further research, including ongoing trials, is crucial to refine HIA therapy.
- The HIA route may be particularly advantageous for delivering novel biologic agents.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...